NCT02583594View on ClinicalTrials.gov

A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 6, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 1, 2021

Conditions
Progressive Multiple Sclerosis
Interventions
DRUG

Acyclovir

Pharmaceutical form:tablet Route of administration: oral

DRUG

Methylprednisolone

Pharmaceutical form:tablet Route of administration: oral

DRUG

alemtuzumab GZ402673

Pharmaceutical form:solution for infusion Route of administration: intravenous

DRUG

alemtuzumab GZ402673

Pharmaceutical form:injection Route of administration: subcutaneous

DRUG

Paracetamol

Pharmaceutical form:tablet Route of administration: oral

DRUG

Loratadine

Pharmaceutical form:tablet Route of administration: oral

DRUG

Ceterizine

Pharmaceutical form:tablet Route of administration: oral

DRUG

Dexchlorpheniramine

Pharmaceutical form:tablet Route of administration: oral

Trial Locations (1)

08035

Investigational Site Number 724001, Barcelona

All Listed Sponsors
lead

Genzyme, a Sanofi Company

INDUSTRY

NCT02583594 - A Study to Characterize Subcutaneous or Intravenous Alemtuzumab in Patients With Progressive Multiple Sclerosis | Biotech Hunter | Biotech Hunter